$0.00
(Market cap
$57 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-19 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.9
-
Debt to Equity
0
-
Book Value
$1
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
147,372,131
10 Years Aggregate
CFO
$-159.49 Mln
EBITDA
$-235.03 Mln
Net Profit
$-261.37 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immutep - ADR
| -86.5 | 0.4 | -11.5 | -76.8 | -41.2 | -36.6 | -18.3 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Immutep - ADR
| 31.8 | -9.5 | 37.1 | -46.6 | 4.5 | 75.4 | -2.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immutep - ADR
|
0.4 | 56.9 | 5.0 | -61.4 | -1,706.4 | -36.9 | -- | 0.8 |
| 13.7 | 914.4 | 0.0 | -175.9 | -- | -106.8 | -- | 5.6 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 12.4 | 2,195.3 | 549.1 | 17.9 | -6.3 | 1.4 | 126.3 | 1.7 | |
| 17.5 | 2,204.8 | 65.4 | -94.4 | -108.2 | -16.1 | -- | 3.9 | |
| 11.7 | 838.7 | 366.5 | 9.3 | 8.3 | 3.4 | 84.6 | 3.1 | |
| 3.6 | 614.9 | 4.1 | -187.9 | -4,613.1 | -233.9 | -- | 0.3 | |
| 13.4 | 824.8 | 0.6 | -59.9 | -9,892.6 | -118.9 | -- | 21.3 | |
| 6.4 | 660.0 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.9 | |
| 26.1 | 2,920.0 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 4.8 |
Shareholding Pattern
View DetailsAbout Immutep - ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble... LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. Read more
-
CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
-
CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
-
Headquarters
Sydney, NSW
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Immutep - ADR
What is the current share price of Immutep Limited - ADR Today?
The share price of Immutep Limited - ADR is $0.38 (NASDAQ) as of 28-Aug-2026 13:38 EDT. Immutep Limited - ADR has given a return of -41.17% in the last 3 years.
What is the current PB & PE ratio of Immutep Limited - ADR?
Since, TTM earnings of Immutep Limited - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.89 |
1.67 |
2024 |
-5.72 |
1.29 |
2023 |
-4.74 |
1.39 |
2022 |
-5.46 |
1.87 |
2021 |
-9.68 |
3.95 |
What is the 52 Week High and Low of Immutep Limited - ADR?
The 52-week high and low of Immutep Limited - ADR are Rs 3.53 and Rs 0.29 as of 29-Aug-2026.
What is the market cap of Immutep Limited - ADR?
Immutep Limited - ADR has a market capitalisation of $ 57 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Immutep Limited - ADR?
Before investing in Immutep Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.